GlassScriptPhysician profile
Paul N Chervin
NPI 1396737714
$36,417.29
in general payments reported to CMS, 2019-2025
44 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 75% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $2,680 · 2021: $1,764 · 2022: $2,233 · 2023: $1,674 · 2024: $1,941 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,841 · Consulting Fee: $150 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,841.39 |
| Consulting Fee | $150.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $25,478.49 | 2019-2024 | Inbrija |
| Abbvie INC. | $1,278.05 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $1,136.16 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biogen, INC. | $954.99 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Kyowa Kirin, INC. | $659.14 | 2020-2024 | Nourianz |
| Lilly USA, LLC | $536.31 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Celgene Corporation | $527.45 | 2021-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $497.18 | 2019-2025 | |
| Eisai INC. | $430.49 | 2021-2025 | |
| Sk Life Science, INC. | $407.68 | 2020-2025 | |
| Acadia Pharmaceuticals INC | $358.95 | 2019-2025 | Nuplazid |
| Lundbeck LLC | $341.12 | 2021-2025 | Vyepti |
| Mdd US Operations, LLC | $321.38 | 2019-2025 | Apokyn, Gocovri, Gocovri |
| Amneal Pharmaceuticals LLC | $301.31 | 2021-2025 | Rytary, Crexont, Ongentys |
| Avanir Pharmaceuticals, INC. | $230.13 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Chervin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.